Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHorowitz, J.en
dc.contributor.authorHeresztyn, T.en
dc.identifier.citationJournal of Chromatography. B, Analytical Techniques in the Biomedical and Life Sciences, 2007; 851(1-2):42-50en
dc.descriptionCopyright © 2006 Elsevier B.V. All rights reserved.en
dc.description.abstractRecent studies among patients including those with known coronary disease demonstrate that small elevations in asymmetric dimethylarginine (ADMA) concentrations in plasma are predictive of adverse outcomes. The precision of current methodologies for quantitation of ADMA such as HPLC, MS and ELISA is discussed with respect to many reports which appear to over-estimate ADMA levels and quote broad concentration ranges. While plasma ADMA concentrations tend to increase with age, the mean for a healthy population is between 0.4 and 0.6 microM. ADMA levels may fluctuate in normal subjects, and this needs to be considered in light of the relatively small differences in ADMA concentration between healthy normal subjects and patients.en
dc.description.statementofresponsibilityJohn D. Horowitz and Tamila Heresztynen
dc.publisherElsevier Science BVen
dc.subjectAnimals; Humans; Disease; Arginine; Chromatography, High Pressure Liquid; Clinical Laboratory Techniques; Health; Mass Spectrometryen
dc.titleAn overview of plasma concentrations of asymmetric dimethylarginine (ADMA) in health and disease and in clinical studies: Methodological considerationsen
dc.typeJournal articleen
dc.provenanceFormerly known as Journal of Chromatography B: Biomedical Sciences and Applicationsen
pubs.library.collectionMedicine publicationsen
dc.identifier.orcidHorowitz, J. [0000-0001-6883-0703]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.